{"entity":{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","aka":["Small cell carcinoma of the cervix","Neuroendocrine carcinoma","Neuroendocrine carcinoma (rare; SCLC-like)","Small cell neuroendocrine carcinoma of the cervix","SCCC"],"tldr":"Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive cervical cancer that behaves like small cell lung cancer, spreading early to nodes and distant organs even when the tumour is small. Fewer than four in ten women with early disease are alive at five years, and treatment combines the cervical cancer approach with the chemotherapy used for small cell lung cancer.","summary":"The WHO classification of female genital tumours lists small cell neuroendocrine carcinoma among the neuroendocrine carcinomas of the cervix, HPV-associated in most cases (usually HPV18). The Gynecologic Cancer InterGroup consensus review describes it as a rare histological entity with a poor outcome because of the high incidence of nodal or distant metastasis even in early stage, and reviews epidemiology, pathology and initial treatment (GCIG 2014). In 188 patients (136 from the literature and 52 from four hospitals), 135 had stage I to IIA, 45 stage IIB to IVA and 8 stage IVB disease; 55.3 percent had surgery, 16.0 percent chemoradiation, 12.8 percent radiation and 3.2 percent chemotherapy alone; five-year disease-specific survival was 36.8 percent for stage I to IIA, 9.8 percent for IIB to IVA and 0 percent for IVB, and adjuvant chemotherapy or chemoradiation was associated with higher survival (Am J Obstet Gynecol 2010).\n\nHow it differs from its parent: it is the cervical cancer in which systemic chemotherapy is part of treatment at every stage, in which brain imaging and prophylaxis are considered, and in which surgery alone is never enough.\n\nHow common: no registry share in the sources read; rare.\n\nTreatment: radical hysterectomy or chemoradiation according to stage, always with platinum and etoposide chemotherapy as for small cell lung cancer; checkpoint inhibitors with chemotherapy are used by analogy with extensive-stage small cell lung cancer, following the extrapulmonary neuroendocrine carcinoma page (GCIG 2014; Am J Obstet Gynecol 2010).","asOf":"2026-09-24","wikipedia":"https://en.wikipedia.org/wiki/Cervical_cancer","links":[{"label":"NCI PDQ: cervical cancer treatment","url":"https://www.cancer.gov/types/cervical/treatment"},{"label":"Am J Obstet Gynecol 2010: small cell carcinoma of the cervix, treatment and survival of 188 patients","url":"https://doi.org/10.1016/j.ajog.2010.04.019"},{"label":"Int J Gynecol Cancer 2014: GCIG consensus review for small cell carcinoma of the cervix","url":"https://doi.org/10.1097/igc.0000000000000262"}],"tags":["subtype-page","wave4","rare"],"related":["cervical","extrapulmonary-nec","cervical-adenosquamous-carcinoma","recurrent-metastatic-cervical-cancer","sclc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin","etoposide","atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["chemoradiation","hpv-p16"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"group":"gynaecologic","burden":"A rare histological entity of cervical cancer (GCIG 2014); the largest pooled analysis holds 188 patients, 135 with stage I to IIA disease (Am J Obstet Gynecol 2010). No registry share is in the sources read.","subtypes":["Small cell neuroendocrine carcinoma of the cervix, early stage (surgery plus platinum-etoposide)","Small cell neuroendocrine carcinoma of the cervix, locally advanced (chemoradiation plus platinum-etoposide)","Large cell neuroendocrine carcinoma of the cervix (related, treated the same)","Mixed neuroendocrine and squamous or adenocarcinoma of the cervix"],"biomarkers":["Synaptophysin, chromogranin and INSM1","HPV18 and p16","Node and distant staging including brain imaging","Ki-67 (very high)"],"standardOfCare":[{"setting":"All stages","approach":"Surgery or chemoradiation by stage, always with platinum and etoposide as for small cell lung cancer; checkpoint inhibitors by analogy with extensive-stage small cell lung cancer.","refs":["cervical","extrapulmonary-nec","cisplatin","etoposide","atezolizumab","chemoradiation"]}],"stateOfArt":[],"history":[],"pipeline":[],"openProblems":[],"parent":"cervical"},"route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","neighbours":{"cancer":[{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/"}]}}